High Grade Glioma Clinical Trials

57 recruitingLast updated: June 18, 2026

There are 57 actively recruiting high grade glioma clinical trials across 27 countries. Studies span Phase 1, Phase 2, Early Phase 1, Not Applicable, Phase 3, Phase 4. Top locations include Columbus, Ohio, United States, Washington D.C., District of Columbia, United States, Philadelphia, Pennsylvania, United States. Updated daily from ClinicalTrials.gov.


High Grade Glioma Trials at a Glance

57 actively recruiting trials for high grade glioma are listed on ClinicalTrialsFinder across 6 cities in 27 countries. The largest study group is Phase 1 with 21 trials, with the heaviest enrollment activity in Columbus, Washington D.C., and Philadelphia. Lead sponsors running high grade glioma studies include Nationwide Children's Hospital, Nader Sanai, and NYU Langone Health.

Browse high grade glioma trials by phase

Treatments under study

About High Grade Glioma Clinical Trials

Looking for clinical trials for High Grade Glioma? There are currently 49 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new High Grade Glioma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about High Grade Glioma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 57 trials

Recruiting
Phase 1Phase 2

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

Brain CancerGBMGlioma+12 more
National Institute of Neurological Disorders and Stroke (NINDS)40 enrolled1 locationNCT07416188
Recruiting
Phase 1

Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

High Grade GliomaLow-grade GliomaRecurrent World Health Organization (WHO) Grade II Glioma
University of California, San Francisco50 enrolled17 locationsNCT04485559
Recruiting
Phase 2

Study of Olutasidenib and Temozolomide in HGG

Metastatic Brain TumorIDH1 MutationAstrocytoma, Grade IV+16 more
Rigel Pharmaceuticals60 enrolled20 locationsNCT06161974
Recruiting
Phase 4

Dabrafenib and/or Trametinib Rollover Study

MelanomaNon-small Cell Lung CancerSolid Tumor+2 more
Novartis Pharmaceuticals100 enrolled29 locationsNCT03340506
Recruiting
Phase 1

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

MelanomaNon-small Cell Lung CancerThyroid Cancer+10 more
Pfizer124 enrolled82 locationsNCT05538130
Recruiting

Targeted Pediatric High-Grade Glioma Therapy

Metastatic Brain TumorGlioblastomaGlioblastoma Multiforme+6 more
Nationwide Children's Hospital350 enrolled21 locationsNCT05839379
Recruiting
Early Phase 1

Multiparametic Metabolic and Hypoxic PET/MRI for Disease Assessment in High Grade Glioma

High Grade Glioma
University of Alabama at Birmingham20 enrolled2 locationsNCT05632562
Recruiting
Not Applicable

Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma

Brain CancerGlioblastomaGBM+4 more
Northwell Health32 enrolled1 locationNCT05954858
Recruiting
Not Applicable

Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)

Brain CancerGlioblastomaGBM+5 more
Northwell Health10 enrolled1 locationNCT05979064
Recruiting
Phase 2

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

Metastatic Brain TumorGlioblastomaGlioblastoma Multiforme+7 more
Nationwide Children's Hospital120 enrolled20 locationsNCT05843253
Recruiting
Phase 2

DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma

High Grade GliomaAnaplastic Astrocytoma
Ashish Shah33 enrolled1 locationNCT06264388
Recruiting
Phase 2

Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors

RecurrenceRefractoryHigh Grade Glioma+4 more
Clinica Universidad de Navarra, Universidad de Navarra39 enrolled2 locationsNCT07424092
Recruiting
Phase 2

ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas

Diffuse Intrinsic Pontine Gliomas (DIPG)Progressive DIPGRefractory DIPG+2 more
Nationwide Children's Hospital60 enrolled20 locationsNCT06838676
Recruiting
Phase 2

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

CNS TumorHigh Grade Glioma
St. Jude Children's Research Hospital52 enrolled6 locationsNCT06528691
Recruiting
Phase 2

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

High Grade GliomaDiffuse Intrinsic Pontine GliomaRecurrent Medulloblastoma
Nationwide Children's Hospital120 enrolled13 locationsNCT05096481
Recruiting
Phase 1

Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progression

GlioblastomaHigh Grade Glioma
Case Comprehensive Cancer Center10 enrolled1 locationNCT05565118
Recruiting
Early Phase 1

Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)

Brain CancerGliomaHigh Grade Glioma+4 more
Eben Rosenthal38 enrolled1 locationNCT07210632
Recruiting
Phase 1

Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors

Central Nervous System NeoplasmsGlioblastomaHigh Grade Glioma+4 more
St. Jude Children's Research Hospital48 enrolled1 locationNCT05835687
Recruiting
Phase 1

C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)

High Grade GliomaDiffuse Intrinsic Pontine GliomaEmbryonal Tumor+1 more
Baylor College of Medicine56 enrolled1 locationNCT04099797
Recruiting
Phase 1

A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)

High Grade GliomaAdult GlioblastomaWHO Grade III or IV Malignant Glioma
University of Florida28 enrolled1 locationNCT04573140